Cargando…

Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data

BACKGROUND: SMYD2 is a protein of the SET and MYND domain-containing family SMYD. It can methylate the lysine residue of various histone and nonhistone cancer-related proteins and plays a critical role in tumorigenesis. Although emerging evidence supports the association of SMYD2 in the progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Arvind Kumar, Singh, Tiratha Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654300/
https://www.ncbi.nlm.nih.gov/pubmed/37971632
http://dx.doi.org/10.1186/s43141-023-00594-7
_version_ 1785147828271579136
author Yadav, Arvind Kumar
Singh, Tiratha Raj
author_facet Yadav, Arvind Kumar
Singh, Tiratha Raj
author_sort Yadav, Arvind Kumar
collection PubMed
description BACKGROUND: SMYD2 is a protein of the SET and MYND domain-containing family SMYD. It can methylate the lysine residue of various histone and nonhistone cancer-related proteins and plays a critical role in tumorigenesis. Although emerging evidence supports the association of SMYD2 in the progression of cancers, but its definitive effect is not yet clear. Therefore, further study of the gene in relation with cancer progression needs to be conducted. In the current study, investigators used TCGA data to determine the potential carcinogenic effect of SMYD2 in 11 cancer types. The transcriptional expression, survival rate, mutations, enriched pathways, and Gene Ontology of the SMYD2 were explored using different bioinformatics tools and servers. In addition, we also examined the correlation between SMYD2 gene expression and immunocyte infiltration in multiple cancer types. RESULTS: Findings revealed that higher expression of SMYD2 was significantly correlated with cancer incidents. In CESC and KIRC, the mRNA expression of SMYD2 was significantly correlated with overall survival (OS). In BRCA, KIRC, COAD, and HNSC, the mRNA expression of SMYD2 was significantly correlated with disease-free survival (DFS). We detected 15 missense, 4 truncating, 4 fusions, and 1 splice type of mutation. The expression of SMYD2 was significantly correlated with tumor purity and immunocyte infiltration in six cancer types. The gene GNPAT was highly associated with SMYD2. Significant pathways and Gene Ontology (GO) terms for co-expressed genes were associated to various processes linked with cancer formation. CONCLUSION: Collectively, our data-driven results may provide reasonably comprehensive insights for understanding the carcinogenic effect of SMYD2. It suggests that SMYD2 might be used as a significant target for identifying new biomarkers for various human tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-023-00594-7.
format Online
Article
Text
id pubmed-10654300
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106543002023-11-16 Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data Yadav, Arvind Kumar Singh, Tiratha Raj J Genet Eng Biotechnol Research BACKGROUND: SMYD2 is a protein of the SET and MYND domain-containing family SMYD. It can methylate the lysine residue of various histone and nonhistone cancer-related proteins and plays a critical role in tumorigenesis. Although emerging evidence supports the association of SMYD2 in the progression of cancers, but its definitive effect is not yet clear. Therefore, further study of the gene in relation with cancer progression needs to be conducted. In the current study, investigators used TCGA data to determine the potential carcinogenic effect of SMYD2 in 11 cancer types. The transcriptional expression, survival rate, mutations, enriched pathways, and Gene Ontology of the SMYD2 were explored using different bioinformatics tools and servers. In addition, we also examined the correlation between SMYD2 gene expression and immunocyte infiltration in multiple cancer types. RESULTS: Findings revealed that higher expression of SMYD2 was significantly correlated with cancer incidents. In CESC and KIRC, the mRNA expression of SMYD2 was significantly correlated with overall survival (OS). In BRCA, KIRC, COAD, and HNSC, the mRNA expression of SMYD2 was significantly correlated with disease-free survival (DFS). We detected 15 missense, 4 truncating, 4 fusions, and 1 splice type of mutation. The expression of SMYD2 was significantly correlated with tumor purity and immunocyte infiltration in six cancer types. The gene GNPAT was highly associated with SMYD2. Significant pathways and Gene Ontology (GO) terms for co-expressed genes were associated to various processes linked with cancer formation. CONCLUSION: Collectively, our data-driven results may provide reasonably comprehensive insights for understanding the carcinogenic effect of SMYD2. It suggests that SMYD2 might be used as a significant target for identifying new biomarkers for various human tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-023-00594-7. Springer Berlin Heidelberg 2023-11-16 /pmc/articles/PMC10654300/ /pubmed/37971632 http://dx.doi.org/10.1186/s43141-023-00594-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Yadav, Arvind Kumar
Singh, Tiratha Raj
Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
title Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
title_full Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
title_fullStr Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
title_full_unstemmed Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
title_short Computational approach for assessing the involvement of SMYD2 protein in human cancers using TCGA data
title_sort computational approach for assessing the involvement of smyd2 protein in human cancers using tcga data
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654300/
https://www.ncbi.nlm.nih.gov/pubmed/37971632
http://dx.doi.org/10.1186/s43141-023-00594-7
work_keys_str_mv AT yadavarvindkumar computationalapproachforassessingtheinvolvementofsmyd2proteininhumancancersusingtcgadata
AT singhtiratharaj computationalapproachforassessingtheinvolvementofsmyd2proteininhumancancersusingtcgadata